Business Context and Reporting Period
Company: Assembly Biosciences, Inc. (ASMB)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Assembly Biosciences is a biotechnology company developing therapeutics for serious viral diseases, including recurrent genital herpes (HSV), hepatitis delta virus (HDV), hepatitis B virus (HBV), and transplant-associated herpesviruses. The company has no approved products and relies on its pipeline and strategic collaborations for future revenue.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $72.3 million | $28.5 million |
| Total Operating Expenses | $84.4 million | $73.9 million |
| Research & Development (R&D) Expenses | $64.8 million | $55.9 million |
| General & Administrative (G&A) Expenses | $19.6 million | $18.0 million |
| Net Loss | $(6.1) million | $(40.2) million |
| Cash, Cash Equivalents & Marketable Securities | $248.1 million | $112.1 million |
| Accumulated Deficit | $(832.0) million | $(825.9) million |
Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product sales revenue.
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased 154% to $72.3 million, primarily driven by a $35.0 million opt-in fee recognized in December 2025 when Gilead exercised its option to license the HPI program (ABI-5366 and ABI-1179). An additional $10.0 million payment received in late 2024 was largely recognized in 2025.
- Reduced Net Loss: Net loss narrowed significantly from $40.2 million in 2024 to $6.1 million in 2025, largely due to the spike in collaboration revenue offsetting increased operating costs.
- Increased R&D Spend: R&D expenses rose 16% to $64.8 million, driven by higher external program costs for the HPI candidates (5366 and 1179) as Phase 1a/b studies progressed, and increased employee compensation.
- Capital Raise: The company raised significant capital in August 2025 through an underwritten offering and a private placement with Gilead, resulting in net proceeds of approximately $166.4 million. This increased total cash and marketable securities to $248.1 million.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Liquidity: Management believes current funds ($248.1 million) are sufficient to meet operating requirements into 2028.
- Gilead Collaboration: Gilead exercised its option for the HPI program in December 2025. Assembly expects to receive Gilead's development plan and budget by mid-2026 to decide on a "Profit-Share" arrangement (covering 40% of US R&D costs for 40% of US profits). Gilead is expected to initiate Phase 2 studies for the HPI program in 2026.
- Pipeline Progress:
- HDV (ABI-6250): Phase 2 initiation expected in Q4 2026.
- HBV (ABI-4334): Gilead declined to exercise its option in March 2026. Assembly retains full control and is actively seeking partners; the company does not plan to advance this candidate without a partner.
- Transplant Herpesviruses (ABI-7272): Transitioned from prodrug 7423 to parent molecule 7272 in October 2025; currently in regulatory filing-enabling studies.
Risks and Contingencies
- Dependence on Gilead: The company relies heavily on the Gilead collaboration for funding and future commercialization of key assets. Termination or failure of this collaboration would materially harm the business.
- Profitability: The company has no approved products and expects to continue incurring substantial losses until product candidates are approved and commercialized.
- Regulatory and Clinical Risks: Clinical studies are expensive and time-consuming; failure to demonstrate safety or efficacy could halt development. Regulatory approval processes are unpredictable.
- Third-Party Reliance: The company relies on Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) for clinical trials and manufacturing, introducing supply chain and quality control risks.
- Geopolitical and Operational Risks: Risks include potential disruptions from U.S. government shutdowns affecting customs, cybersecurity threats, and reliance on vendors in locations outside the U.S., including China.
Investor Verification Checklist
- Gilead Profit-Share Decision: Verify the timeline and outcome of Assembly's decision to opt-in to the 40% cost/profit share for the HPI program in the U.S., expected by mid-2026.
- ABI-4334 Partnership: Monitor progress in securing a new partner for the HBV candidate (ABI-4334) following Gilead's decision not to exercise its option.
- Cash Burn Rate: Track quarterly cash usage to confirm the runway extends into 2028 as projected, given the high R&D spend.
- Clinical Data Readouts: Watch for Phase 2 data readouts for the HPI program (anticipated 2026) and Phase 2 initiation for the HDV candidate (ABI-6250) in Q4 2026.
- Regulatory Filings: Monitor the status of regulatory filing-enabling studies for the transplant-associated herpesvirus candidate (ABI-7272).